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ABSTRACT Nitric oxide produced by cytokine-inducible
nitric oxide synthase (iNOS) is thought to be important in the
pathogenesis of septic shock To further our understanding of
the role of iNOS in normal biology and in a variety of inflam-
matory disorders, including septic shock, we have used gene
targeting to generate a mouse strain that lacks iNOS. Mice
lacking iNOS were indistinguishable from wild-type mice in
appearance and histology. Upon treatment with lipopolysac-
charide and interferon y, peritoneal macrophages from the
mutant mice did not produce nitric oxide measured as nitrite
in the culture medium. In addition, lysates of these cells did
not contain iNOS protein by immunoblot analysis or iNOS
enzyme activity. In a Northern analysis of total RNA, no iNOS
transcript of the correct size was detected. No increases in
serum nitrite plus nitrate levels were observed in homozygous
mutant mice treated with a lethal dose of lipopolysaccharide,
but the mutant mice exhibited no significant survival advan-
tage over wild-type mice. These results show that lack ofiNOS
activity does not prevent mortality in this murine model for
septic shock
In biological systems, nitric oxide (NO) is produced via the
oxidation of L-arginine by enzymes known as nitric oxide
synthases (NOSs). Three NOS isozymes have been described
(for recent reviews see refs. 1 and 2). These include constitu-
tively expressed neuronal (3, 4) and endothelial (5, 6) enzymes
and a cytokine-induced enzyme found in macrophages (7),
hepatocytes (8), and a variety of other cells (9, 10). Although
the biological functions of these enzymes are not completely
understood, neuronal NOS is thought to play a role in neu-
rotransmission (11), endothelial NOS is involved in regulation
ofvascular tone (12, 13), and inducible NOS (iNOS) is involved
in immune defense (14, 15). The constitutively synthesized
neuronal and endothelial enzymes produce small amounts of
NO in response to increases in intracellular calcium levels. In
contrast, iNOS is synthesized de novo in response to a variety
of inflammatory stimuli and produces large amounts of NO
over prolonged periods of time (16). NO produced by iNOS
has been shown to be beneficial through its antitumor (17, 18)
and antimicrobial (15) activities, but it is also thought to cause
tissue damage and contribute to pathology in a variety of
inflammatory conditions including rheumatoid arthritis (19,
20), inflammatory bowel disease (21), and septic shock (22,
23).
Septic shock is usually the result of a systemic Gram-negative
bacterial infection and is characterized by hypotension and the
failure of a number of organ systems, especially the liver,
kidney, and heart (24). The bacterial membrane component,
lipopolysaccharide (LPS), induces the production of host
inflammatory mediators such as tumor necrosis factor a,
interferon y (IFN-,y), and interleukin 1,B, which in turn cause
an increase in the expression of iNOS. The large amount ofNO
produced by iNOS has been hypothesized to contribute to
LPS-induced hypotension and mortality.
To better understand the biological function of NO pro-
duced by iNOS and to determine whether overproduction of
NO plays a crucial role in septic shock, we have used homol-
ogous recombination in embryonic stem (ES) cells to disrupt
the iNOS gene. From these cells we generated mice that lack
iNOS. The mice lacking iNOS were then examined in an
LPS-induced model of septic shock.
MATERIALS AND METHODS
Design of Targeting Construct. A library of A bacterio-
phages carrying fragments derived from a partial Mbo I digest
of mouse strain 129 genomic DNA was screened with a
fragment of the murine iNOS cDNA (25) that contained the
calmodulin-binding domain. A A bacteriophage containing a
14-kb DNA fragment was isolated, from which a 12-kb EcoRI
fragment containing the calmodulin-, FMN-, and FAD-bind-
ing domains of iNOS was subcloned into pBluescript II SK
(Stratagene). The targeting construct, pSPKO-NOS (see Fig.
1), consisted of a 9-kb Sph I-EcoRI fragment in which theApa
I-Kpn I fragment containing the calmodulin-binding domain
was replaced by the neomycin resistance gene from pMClNeo
polA (27). A copy of the herpes simplex virus thymidine kinase
gene was introduced into the construct to allow positive-
negative selection (28). Before electroporation, pSPKO-NOS
was linearized with Hpa I.
ES Cell Transfection and Selection. The 129-derived ES cell
line E14TG2a (29) was cultured on irradiated primary embry-
onic fibroblast-feeder layers in Dulbecco's modified Eagle
medium-H, as described (30). Electroporation was essentially
as described (31). In 0.8 ml of medium, 3 x 107 ES cells were
mixed with 22 ,ug of the linearized pSPKO-NOS targeting
construct and electroporated using the Gene Pulser (Bio-Rad)
at 230 V and 500 ,LF. Cells were then transferred to 10-cm-
diameter feeder plates. Medium was replaced the following
day with medium containing G418 (200 ,ug/ml) and ganciclo-
vir (2 ,ug/ml). Drug-resistant colonies were grown in 16-mm-
diameter wells and transferred to 35-mm-diameter wells. Sub-
sequently, half of each culture was lysed for PCR analysis.
Recombinants were identified by PCR using the primers a and
b as illustrated in Fig. 1. Primer a was 5'-GACAGGTGT-
GAGCTACCACATCTGAGTC-3' and is complementary to a
region of the iNOS gene that was not included in the targeting
construct, and primer b was 5'-ACTGCTCGACATTGGGT-
GGAAACATTCC-3' and is complementary to the incoming
neomycin resistance gene. PCR was performed on 500 ng of
genomic DNA for 28 cycles of 1 min at 95°C, 1 min at 60°C,
Abbreviations: NO, nitric oxide; NOS, nitric oxide synthase; iNOS,
inducible nitric oxide synthase; IFN--y, interferon y; LPS, lipopoly-
saccharide; ES, embryonic stem; B6, C57BL/6J; NO., nitrite plus
nitrate; CALM, calmodulin-binding domain of mouse iNOS cDNA.
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and 2 min at 72°C using a DNA thermo cycler (Perkin-Elmer).
Southern analysis was used to confirm PCR-identified recom-
binants.
Generation of Mice Lacking iNOS. To generate chimeric
mice, C57BL/6J (B6) blastocysts were injected with the re-
combinant ES cells and implanted into pseudopregnant fe-
males as described (32). Chimeric males were mated with B6
females, and the resulting B6/129 F1 heterozygotes were
mated to generate F2 mice homozygous for the iNOS disrup-
tion. Genotyping of mice was performed by Southern analysis
of BamHI-digested tail DNA. Mice were housed under patho-
gen-free conditions.
The experiments described in this paper used 7- to 10-week-
old male and female wild-type (+/+), heterozygous mutant
(+/-), and homozygous mutant (-/-) mice from the F2
generation. Wild-type B6 mice (The Jackson Laboratory) were
also used where indicated. In one LPS-induced shock exper-
iment, F1 (B6/129) mice were used.
Nucleic Acid Analysis. For Southern analysis, 10 jig of
genomic DNA from tails was digested with BamHI, electro-
phoresed on 0.8% agarose gels, and transferred to Zeta-Probe
membranes (Bio-Rad). Hybridization was done as recom-
mended by the manufacturer. The probe was a 500-bpBamHI-
Xmn I genomic fragment (Fig. 1).
For Northern analysis, total RNA was isolated using TRIzol
reagent (Life Technologies, Gaithersburg, MD). Samples (10
,ug) were electrophoresed on 1% agarose gels containing
formaldehyde, transferred to positively charged nylon mem-
branes (Boehringer Mannheim), and hybridized using Ex-
pressHyb solution (Clontech). Probes used in Northern anal-
ysis were as follows: cDNA, mouse iNOS cDNA (25); CALM,
the calmodulin-binding domain of mouse iNOS cDNA (33);
and GAPDH, glyceraldehyde-3-phosphate dehydrogenase
cDNA (34).
Macrophage Culture. Macrophages were elicited by treating
mice with an i.p. injection of 2 ml of 4% Brewer thioglycollate
(Difco). Four days later, cells were harvested by washing out
the peritoneal cavity with 20 ml of cold phosphate-buffered
saline solution. The cells were washed once with RPMI 1640
medium (Life Technologies)/10% fetal bovine serum and
placed in 35-mm-diameter wells (four wells per mouse). After
3 hr at 37°C, nonadherent cells were removed by three washes
with complete medium. For induction of iNOS, the adherent
FIG. 1. Targeted disruption of the mouse iNOS gene.
B The targeting construct pSPKO-NOS (Top), the mouse
iNOS genomic region including exons 11-19 (Middle),
_.4 and the recombinant locus (Bottom) are illustrated.
Exons (represented by boxes) are numbered by analogy
to the human iNOS gene (26). Solid boxes indicate
cofactor-binding domains, iNOS genomic sequences are
indicated by a thick line, and plasmid sequences are
indicated by a thin line. Relevant restriction sites areApa
I (A), BamHI (B), EcoRI (E), Hpa I (H), Kpn I (K), Sph
I (S), and Xmn I (X). The Apa I-Kpn I fragment
B containing the calmodulin-binding domain was replaced
by the neomycin resistance gene. Primers specific for an
4 intronic sequence 5' of the targeting vector (arrow a) or
the neomycin resistance gene (arrow b) were used for
PCR screening of ES cells. The probe used to genotype
ES cell and mouse tail DNA by Southern analysis is
indicated at the bottom.
cells were treated with murine IFN-,y at 100 units/ml (Boeh-
ringer Mannheim) and LPS at 1 gg/ml (Escherichia coli
0111:B4, List Biological Laboratories, Campbell, CA). After
10-12 hr, cells were harvested for the preparation of RNA or
cell lysates. Cell lysates were prepared by resuspending cells in
20 mM Tris-HCl, pH 7.5, containing 1 mM dithiothreitol and
10 ,M tetrahydrobiopterin, and lysing by three cycles of
freeze-thaw.
Immunoblot Analysis. Immunoblot analysis was done on
lysates of cultured peritoneal macrophages by conventional
procedures using a rabbit polyclonal antibody to murine iNOS
(Transduction Laboratories, Lexington, KY) and an alkaline
phosphatase-conjugated secondary antibody (Protoblot Sys-
tem, Promega).
NOS Activity and Nitrite/Nitrate Analysis. NOS activity in
macrophage lysates was determined by the conversion of
14C-labeled L-arginine to L-citrulline (35) as described (36).
Nitrite in macrophage culture supernatants was measured spec-
trophotometrically as described (36) using the Griess reagent (1%
sulfanilamide/0.1% naphthylethylenediamine/2% phosphoric
acid). Nitrite plus nitrate (NO,) was measured in mouse serum
samples. To do this, blood was obtained by cardiac puncture,
centrifuged after clotting, and deproteinized by filtration through
a Millipore Ultrafree-MC (NMWL30,000) filter unit. Nitrate was
enzymatically reduced to nitrite with nitrate reductase (Boeh-
ringer Mannheim), and nitrite was then determined spectropho-
tometrically.
LPS Treatment and Histology of Mice. Mice were injected
i.p. with bacterial LPS at 12.5 or 25 mg/kg (E. coli, serotype
026:B6, Difco). Tissues were collected from euthanized mice
or from mice that died after LPS treatment, fixed in formalin,
and stained with hematoxylin/eosin.
RESULTS
Targeted Disruption of Mouse iNOS Gene in ES Cells. The
targeting strategy used to inactivate the iNOS gene by homol-
ogous recombination is outlined in Fig. 1. After homologous
recombination, the calmodulin-binding domain of iNOS is
replaced by the neomycin resistance gene, and the reading
frame of the modified gene is disrupted. Calmodulin binds
tightly to iNOS and is required for electron transfer from
NADPH to the iron heme group (37, 38). Removing the
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calmodulin-binding domain was therefore expected to result in
an inactive iNOS. The targeting construct was introduced into
ES cells by electroporation, and clones resistant to both G418
and ganciclovir were isolated and screened by PCR using
primers a and b (Fig. 1), which amplify a 1.6-kb product only
after homologous recombination. Clones positive by PCR were
confirmed by Southern analysis of BamHI-digested genomic
DNA. Of 108 doubly-resistant clones screened, 6 contained the
desired mutation.
Generation of iNOS -/- Mice. Two targeted ES clones,
derived from independent electroporations, were microin-
jected into 3.5-day-old B6 blastocysts that were then implanted
into pseudopregnant mice for development. Male chimeras
were bred with B6 females, and offspring heterozygous for the
disrupted iNOS gene were identified by Southern analysis of
BamHI-digested tail DNA.
To obtain mice homozygous for the disrupted iNOS gene,
the F1 B6/129 mutant heterozygotes were interbred, and their
progeny were genotyped by Southern analysis. Fig. 2 shows a
representative Southern blot of BamHI-digested genomic
DNA; the probe hybridized to a 14-kb fragment from the wild-
type allele and to a 5-kb fragment from the mutant allele. Of
266 mice genotyped, 71 (27%) were wild type (+/+), 130
(49%) were heterozygous mutant (+/-), and 65 (24%) were
homozygous mutant (- / -), which does not differ significantly
from the normal Mendelian distribution (P = 0.81 by x test).
The F2 mice heterozygous and homozygous for the iNOS
disruption were indistinguishable from wild-type F2 mice in
appearance, growth rate, reproduction, and histology. Tissues
that were examined included liver, heart, aorta, lung, stomach,
intestine, kidney, brain, muscle, pancreas, spleen, salivary
gland, thymus, tongue, adrenal gland, and bone.
Analysis of iNOS mRNA in Macrophages from iNOS-/-
Mice. The expression of iNOS mRNA in cultured peritoneal
macrophages from mice of the F2 generation (Fig. 3A) was
examined. Eleven hours after LPS/IFN-y treatment, total
RNA was prepared and subjected to Northern analysis with
two different murine iNOS-specific probes. Both the cDNA
and CALM probes hybridized to a single transcript in iNOS
+ /+ and + /- macrophages. No transcript was detected with
the CALM probe in iNOS -/- macrophages. Low levels of
two abnormal transcripts were detected with the cDNA probe
in iNOS -/- macrophages: one transcript was slightly smaller
(-4 kb), and one was significantly larger (=5.1 kb) than the
4.4-kb iNOS transcript detected in iNOS +1+ and +/-
macrophages. Both abnormal transcripts also hybridized to a
neomycin probe (data not shown). These observations confirm
that the calmodulin-binding domain was targeted and indicate
14 kb - S.-
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FIG. 2. Southern blot analysis of mouse tail DNA. Genomic DNA
(10 jig) was digested with BamHI and hybridized to the indicated
probe (Fig. 1). Samples from iNOS +/+, +/-, and -/- mice of the
F2 generation are shown (lane designations). Bands corresponding to
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FIG. 3. Expression of iNOS mRNA and protein in F2 mouse
peritoneal macrophages treated with IFN-y and LPS. (A) Northern
analysis. Total RNA (10 ,g per lane) from iNOS +/+, +/-, and -/-
mouse macrophages was electrophoresed. Hybridization was to the
murine iNOS cDNA probe (Top), a probe (CALM) specific for the
calmodulin-binding sequence of the iNOS cDNA (Middle), and a
probe specific for glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) (Bottom). (B) Immunoblot analysis. Lysate (10 jig of total
protein per lane) was electrophoresed on a SDS/7.5% polyacrylamide
gel. iNOS was detected with a rabbit polyclonal antibody to murine
iNOS. Lysates were from RAW 264.7 cells either untreated (U) or
treated with LPS/IFN-y (I), and from peritoneal macrophages from
iNOS +/+ + -, and -/- mice treated with LPS/IFN--y. The arrow
shows the band corresponding to the 130-kDa iNOS protein.
that the transcripts detected in iNOS - /- macrophages
include sequences from both the iNOS and neomycin resis-
tance genes.
Absence of iNOS Protein in Macrophages from iNOS-/-
Mice. Peritoneal macrophages from thioglycollate-treated
mice were cultured. Eleven hours after treatment with LPS/
IFN-,y, culture supernatants were assayed for nitrite, a stable
oxidation product of NO indicative of iNOS activity. The level
of nitrite was 70 ,uM in the culture medium of macrophages
from iNOS +/+ mice, 36 ,uM for +/- macrophages, and <1
,uM for - /- macrophages (medium control was < 1 ,uM). All
cultures contained approximately equal numbers of cells.
In a more sensitive method for measuring NOS activity, the
conversion of 14C-labeled L-arginine to citrulline was deter-
mined in lysates of LPS/IFN-,y-treated macrophages. The
NOS activity was 950 pmol/min per mg of protein in iNOS
+/+ macrophages, 590 in +/- macrophages, and 60 in -/-
macrophages. The activity detected in macrophages from
iNOS +/+ and +/- mice was inhibited >80% by 50 ,uM
NG-methyl-L-arginine, a specific inhibitor of NOS, but not by
1 mM EGTA or 50 MuM trifluoperazine (a calmodulin antag-
onist). The low level of activity detected in macrophages from
iNOS -/- mice was not inhibited by NG-methyl-L-arginine,
EGTA, or trifluoperazine. Taken together, these results show
that the slight activity detected in macrophages from iNOS
-/- mice was not due to iNOS, or a constitutive isoform of
NOS; it may be due to arginase or some other arginine or
citrulline metabolizing enzyme. A similar level of activity was
detected in macrophages from iNOS +/+ mice that were not
treated with LPS/IFN--y (data not shown).
To confirm the absence of iNOS protein, immunoblot
analysis was done on lysates of LPS/IFN-,y-treated macro-
phages using a polyclonal antibody to murine iNOS (Fig. 3B).
Lysates from iNOS +/+ and +/- macrophages contained the
same 130-kDa immunoreactive protein that was induced in
RAW 264.7 cells, a murine macrophage cell line that expresses
iNOS after LPS/IFN--y treatment (7). In contrast, lysates from
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iNOS -/- macrophages contained no detectable iNOS by
immunoblot analysis.
LPS-Induced Shock in iNOS -- Mice. Generation of NO
by iNOS has been thought to play an important role in the
pathogenesis of septic shock (22, 39, 40). To evaluate the
effects of iNOS deficiency on survival in an LPS-induced
model for septic shock, mice were treated i.p. with LPS at
either 12.5 or 25 mg/kg, and mortality was monitored over a
96-hr period. The higher dose of LPS was chosen because
preliminary tests showed that it led to a mortality rate of >90%
in wild-type B6 and in B6/129 F1 iNOS +/+ mice. The lower
dose was chosen to allow the assessment of the effects of iNOS
genotype when more wild-type survivors would be expected.
F2 mice of the three iNOS genotypes (+/+, +/-, and -/-)
were tested at both doses. Wild-type B6 mice were also tested
at the high dose.
The results of these experiments are shown in Fig. 4. Each
experiment contained equal numbers of mice of each geno-
type. There were no deaths in saline-treated wild-type B6 mice.
At the high dose all LPS-treated wild-type B6 (23 of 23), 90%
of F2 iNOS +/+ (18 of 20), 95% of F2 +/- (19 of 20), and
85% of F2 -/- mice (17 of 20) died by 96 hr. Neither the +/-
nor the -/- mice exhibited a statistically significant survival
advantage over the +/+ mice (P = 0.54 for +/+ versus +/-
and 0.63 for +/+ versus -/- by x2 test). At the lower dose,
73% of F2iNOS +/+ (8 of 11), 64% of +/-(7 of 11), and 91%
of -/- mice (10 of 11) died by 96 hr. Again, there was no
significant difference in survival among the genotypes (P =
0.65 for +/+ versus +/- and 0.27 for +/+ versus -/- by x2
test).
An experiment was also done with B6/129 F1 iNOS +/+
and +/- mice. The F1 mice provide a completely uniform
genetic background for investigating the effect of heterozy-
gosity. These mice were treated with LPS at 25 mg/kg, and as
with the F2 mice, survival of F1 iNOS +/- mice did not differ
significantly from F1 iNOS +/+ mice (11 of 12 +/+ and 10
of 12 +/- mice died by 96 hr, P = 0.76 by x2 test).
Necropsies were done on several F2 mice of each genotype
that died after LPS treatment. No consistent gross pathologic
changes were observed. Microscopically, all mice had apopto-
sis (based on the presence of apoptotic bodies) of lymphocytes
in the spleen and thymus. Apoptosis was more extensive in
+/+ and +/- mice than in -/- mice. Several mice had












FIG. 4. Survival of LPS-treated mice. B6 mice and iNOS +/+,
+/-, and -/- mice of the F2 generation were treated i.p. with LPS
at either 12.5 mg/kg (open symbols) or 25 mg/kg (closed symbols), and
survival was monitored over 4 days.
eration of the adrenal cortex, but neither the incidence nor
severity of the changes varied consistently with the genotype.
LPS-Induced Changes in Blood NO,. Wild-type B6 mice and
F2 mice of the three iNOS genotypes were treated with LPS at
25 mg/kg, and four mice from each group were sacrificed 16
hr later. Blood was obtained by cardiac puncture, and nitrite
was quantitated in the serum after enzymatic conversion of
nitrate to nitrite. The following results were obtained: the
serum NO. level was 16 ± 10 ,uM for saline-treated wild-type
B6 mice, 681 + 187 ,tM for LPS-treated wild-type B6 mice, 6
+ 0.5 ,uM for saline-treated F2 iNOS +/+ mice, 626 + 175 ,uM
for LPS-treated F2 +/+ mice, 370 ± 119 ,uM for LPS-treated
F2 +/- mice, and 19 ± 9 ,uM for LPS-treated F2 -/- mice.
These data show that the F2 iNOS -/- mice have <4% of the
serum NO, levels of the F2 iNOS +/+ mice after LPS
treatment.
DISCUSSION
Although many physiological functions have been ascribed to
NO, independent disruptions of the genes for all three NOS
isozymes are now known to result in viable, fertile mice.
Disruption of the neuronal NOS gene causes no histological
abnormalities in the central nervous system, but the stomachs
of these mice are enlarged (41). Mice with a disruption of the
inducible NOS gene (this paper, and refs. 42 and 43) or the
endothelial NOS gene (our unpublished data) are grossly
normal.
Enhanced formation of NO by iNOS in the vasculature has
been implicated in the pathophysiology of septic shock. Evi-
dence for this has come from observations that serum levels of
NO oxidation products (NO,) are elevated in animals and
humans undergoing septic shock (39, 44, 45) and from in vivo
studies with NOS inhibitors (46, 47). However, inhibition of
NOS in rodent models for sepsis has produced conflicting
results: protective (22, 40), nonprotective (48), and even
detrimental effects (49, 50). These studies are complicated by
the fact that most of them used a nonselective NOS inhibitor.
Therefore concomitant inhibition of either or both of the
constitutive isozymes of NOS may have mitigated the effects
of iNOS inhibition. We have avoided this complication by
generating mice that lack iNOS as a consequence of targeted
disruption of the iNOS gene. Our results show that F2 iNOS
-/- mice are not resistant to LPS-induced mortality despite
their essential lack of serum NO, elevations. Likewise, our F1
iNOS +/+ and +/- animals, which are genetically identical
except for the iNOS gene disruption, were both sensitive to
LPS. This result is despite the fact that the +/- animals have
=50% of the normal level of iNOS activity and =50% of the
serum NO. levels of wild-type animals after LPS treatment.
Experiments similar to ours have recently been reported by
two other groups (42, 43). MacMicking et al. (42) observed no
differences in survival between iNOS +/+ and -/- mice
treated with LPS at 5 and 15 mg/kg but a statistically signif-
icant (we calculate P = 0.01 by X test) improvement in survival
of iNOS -/- over +/+ mice treated with LPS at 30 mg/kg.
In contrast, our F2 iNOS -/- mice did not show a statistically
significant survival advantage over F2 iNOS +/+ mice after
treatment with LPS at either 12.5 or 25 mg/kg. Wei et al. (43)
found that iNOS deficiency completely prevented death after
treatment with LPS at 12.5 mg/kg. In contrast, both Mac-
Micking et al. and we observed significant mortality in iNOS
-/- mice at a similar LPS dose.
The discrepancies in the data that have just been described
are likely to have complex causes. The genetic backgrounds of
the mutant mice and the corresponding control mice used in
the three studies differed, and, in general, mouse strains differ
in their sensitivities to LPS (51). We used F1 B6/129 (+/+ and
-/-) and F2 B6/129 (+/+, +/- and -/-) mice that were
genetically equivalent to littermates in our comparisons. Mac-
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Micking et al. (42) compared B6/129-derived +/+ and -/-
animals of an unspecified generation. Wei et al. (43) compared
MF1/129-derived -/- animals of an unspecified generation
with outbred MF1 +/+ animals. Differences in genetic back-
grounds consequently appear the most likely explanation for
the different results from the three studies. In addition,
differences in LPS preparations used in these studies may
contribute to discrepancies. However, whatever the final ex-
planation for the differences may prove to be, our experimen-
tal results allow the clear statement that iNOS -/- mice,
which have virtually no serum NO. response, are as susceptible
to LPS-induced death as their iNOS +/+ littermates that have
a normal serum NO, response. Thus a genetically caused
absence of NO produced by iNOS does not prevent mortality
in this murine model for septic shock.
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